Biotech | August 02, 2022
UBC acquires Examoto
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
HYMPAVZI’s safety profile was generally favorable
While Merck can appeal, Halozyme said it expects the order to hold
Subscribe To Our Newsletter & Stay Updated
